How MK-677 (Ibutamoren) Affects Blood Glucose

MK-677 (ibutamoren) elevates blood glucose through a combination of GH-mediated and ghrelin-mediated pathways:

1. Sustained GH secretion: Unlike physiological GH release (which occurs in discrete pulses, primarily during sleep), MK-677 stimulates continuous GH secretion over 24 hours. This sustained GH exposure creates persistent lipolysis and elevated free fatty acids (FFAs), driving chronic insulin resistance via the Randle cycle (FFA-glucose competition for oxidation in skeletal muscle).
2. Loss of pulsatility: Normal pulsatile GH release allows insulin sensitivity to recover between pulses. MK-677's continuous stimulation eliminates these recovery windows, producing more sustained insulin resistance per unit of GH exposure compared to pulsatile exogenous GH injections.
3. Ghrelin receptor effects: MK-677 activates the growth hormone secretagogue receptor (GHS-R1a), which is expressed not only in the pituitary but also in the pancreas, hypothalamus, and peripheral tissues. Ghrelin receptor activation directly influences glucose homeostasis by modulating pancreatic beta-cell function, hepatic glucose output, and central appetite regulation.
4. Appetite stimulation: MK-677 significantly increases appetite (a well-known side effect), which can lead to higher caloric and carbohydrate intake. This dietary factor compounds the pharmacological glucose-elevating effects.

The Nass et al. (2008) 12-month randomised controlled trial of MK-677 at 25 mg/day in healthy older adults documented significant increases in fasting glucose, HbA1c, and fasting insulin, confirming the clinical relevance of these mechanisms.

Low dose (10-15 mg/day):

• Fasting glucose may rise 5-10 mg/dL above baseline
• Most users remain below 100 mg/dL
• Insulin resistance is mild but detectable via HOMA-IR
• Appetite increase is moderate

Standard dose (25 mg/day):

• Fasting glucose commonly rises 10-20 mg/dL
• Some users enter the pre-diabetic range (100-125 mg/dL) within weeks
• HOMA-IR frequently rises above 2.0
• Nass et al. (2008) documented a mean fasting glucose increase of approximately 7 mg/dL at 25 mg/day over 12 months, with some subjects exceeding pre-diabetic thresholds

Comparative context (MK-677 vs exogenous GH):

• MK-677 at 25 mg/day typically raises IGF-1 to levels equivalent to 2-3 IU/day of exogenous GH
• However, the glucose impact may be disproportionately larger due to the continuous (non-pulsatile) GH stimulation
• Users who tolerate 3 IU of exogenous GH may find 25 mg of MK-677 more metabolically disruptive

Timeline: Glucose elevation begins within the first 1-2 weeks and can progress over months. The effect appears to be somewhat cumulative with prolonged use, though individual variation is substantial.

Baseline: Obtain fasting glucose, fasting insulin, and HbA1c before starting MK-677. Calculate baseline HOMA-IR. If any baseline values are borderline (fasting glucose above 95, HbA1c above 5.4%, HOMA-IR above 1.5), MK-677 use carries elevated metabolic risk.

During use:

• Fasting glucose: monthly for the first 3 months, then every 3 months
• Fasting insulin: at 1 month and then every 3-6 months (calculate HOMA-IR each time)
• HbA1c: every 3 months (integrates cumulative glucose exposure)
• Monitor weight and appetite: uncontrolled appetite-driven caloric excess will compound glucose problems

Warning signs requiring dose reduction or cessation:

• Fasting glucose consistently above 100 mg/dL
• HOMA-IR above 2.0 (or a significant upward trend from baseline)
• HbA1c above 5.6%
• Symptoms of insulin resistance: post-meal fatigue, excessive thirst, frequent urination, difficulty losing fat despite caloric deficit

Important note: Because MK-677 is typically taken orally once daily (often at night), timing of blood draws relative to dosing matters less than with exogenous GH injections. However, always test in a truly fasted state (10-12 hours).

Dose management:

• Start at 10-15 mg/day rather than 25 mg to assess individual metabolic tolerance
• If glucose rises significantly at 10-15 mg, higher doses will likely be problematic
• Some users find 12.5 mg (half a standard tablet) provides GH benefits with manageable glucose impact

Cycling strategies to reduce metabolic burden:

• 5 days on / 2 days off (weekdays only) allows periodic insulin sensitivity recovery
• 8 weeks on / 4 weeks off cycling reduces cumulative metabolic impact
• Some users pulse MK-677 (3-4 days per week) for a balance between GH elevation and metabolic preservation

Dietary management (especially important due to appetite increase):

• Pre-plan meals to prevent appetite-driven overeating of processed carbohydrates
• High-protein, moderate-fat meals provide satiety without the glucose spike
• If taking MK-677 at night, keep dinner lower in carbohydrates to minimise nocturnal glucose elevation
• Fibre intake of 30-40 g/day slows glucose absorption and improves satiety

Supplement support:

• Berberine 500 mg 2-3x daily (evidence-based insulin sensitiser)
• Chromium picolinate 200-1000 mcg/day
• Alpha-lipoic acid 300-600 mg/day
• Same supplement strategies as exogenous GH (the mechanism of insulin resistance is identical)

If glucose becomes problematic:

• Reduce dose to the minimum effective amount (often 10-12.5 mg)
• Implement cycling if using daily
• Metformin 500-1000 mg/day if HOMA-IR exceeds 2.0 despite lifestyle and supplement measures
• Consider switching to exogenous GH if metabolic effects are unacceptable, as pulsatile GH may be better tolerated